Healthcare Global Enterprises Reports Strong Q1FY27 Performance

Net Sales: ₹695 Cr (up 13.4% YoY)
Adjusted Net Profit: ₹16 Cr (up 175% YoY)

Reader Takeaway: Margin expansion and revenue growth driven by core oncology focus, while managing new facility costs.

What just happened

Healthcare Global Enterprises (HCG) announced its financial results for the first quarter of fiscal year 2027 (Q1FY27). The company reported net sales of ₹695 crore, marking a significant year-on-year growth of 13.4%. Adjusted EBITDA saw a 19.8% increase to ₹134 crore, with the adjusted EBITDA margin improving by 103 basis points to 19.3%. The most striking figure was the adjusted net profit, which surged by an impressive 175% to ₹16 crore.

Why this matters

This strong performance indicates HCG's improving operational efficiency and its successful strategic shifts. The significant jump in net profit suggests better cost management and a healthier revenue stream. The expansion in EBITDA margins points towards increased profitability from its core operations, making the company more attractive to investors looking for growth and efficiency.

The backstory

HCG has been focusing on strengthening its core oncology business. The company recently completed a rights issue, deploying proceeds towards debt reduction and increasing stakes in project entities. It also strategically exited its low-margin fertility business, Milann, at the end of June 2026 to streamline operations.

What changes now

The company's strategic realignment, including the exit from the fertility business and focus on oncology, appears to be yielding positive results. The expansion into a new North Bangalore facility, despite incurring initial startup losses, is showing promise with over 550 new patient registrations in its first quarter. This indicates potential for future revenue streams and market share gains.

Risks to watch

While the quarter was strong, investors should monitor the ramp-up of the new North Bangalore facility and its contribution to profitability. The company also carries startup losses of ₹7 crore from this new facility, which needs to be managed. HCG has long-term EBITDA margin targets of 21.8% in two years and ~25% in 4-5 years, achieving these will be key.

Peer comparison

While specific peer results for the same quarter are not detailed in the filing, HCG's performance, particularly the substantial profit growth and margin expansion, suggests it is carving out a strong position within the Indian healthcare services sector, especially in specialized oncology care.

Context metrics

• Patient Volume: Increased by 11% YoY.
• Average Revenue Per Patient (ARPP): Improved by 2% YoY.
• New Facility Performance: North Bangalore facility recorded over 550 new patient registrations in Q1FY27.
• Debt Repayment: Approximately ₹170 crore of debt was repaid using rights issue proceeds.
• Investment in Projects: Approximately ₹150 crore was deployed to increase equity stakes in project entities.

What to track next

Investors will be keen to observe the continued growth in patient volumes and ARPP. Monitoring the profitability of the North Bangalore facility and its contribution to overall margins will be crucial. HCG's ability to achieve its medium to long-term EBITDA margin targets will also be a key indicator of sustained financial health and operational success.